MannKind's stock surged 7.14% in pre-market trading following the release of its fourth quarter financial results that showed strong revenue growth and a significant sales beat.

The company reported Q4 revenue of $112 million, representing a 46% year-over-year increase. More importantly, sales of $111.955 million substantially exceeded analyst estimates of $97.604 million by 14.70%. The company also reported adjusted earnings per share of $0.01, which met consensus expectations.

Business updates included FDA acceptance of an Afrezza pediatric sBLA with a PDUFA date of May 29, 2026, and FDA acceptance of a Furoscix ReadyFlow Autoinjector sNDA with a PDUFA date of July 26, 2026. The company also noted progress in clinical trials for nintedanib DPI and initiated a Phase 2 IPF trial.